The Memo: Happitech Turning Smartphones into the First Line of Defense for Heart Health

Under the direction of Founder and CEO Yosef Safi Harb, Happitech is rethinking cardiac monitoring with a next-generation smartphone-based platform, a CE-certified solution that enables long-term heart rate and rhythm tracking using only a smartphone, while also integrating with wearables and medical devices equipped with PPG sensors.

By leveraging photoplethysmography (PPG) through a smartphone’s camera and flash, or any compatible sensor or wearable, Happitech delivers medical-grade insights anytime, anywhere. The platform is intended to support clinical decision-making, expand access, and reshape how atrial fibrillation (AFib) is detected and monitored today, and how other heart conditions are detected and monitored tomorrow.

The Current Landscape

Happitech’s foundational belief is that heart monitoring should be accessible, scalable, and effortless. Today, their CE-certified platform is already integrated into more than 50% of Dutch cardiology hospitals and supports long-term cardiac monitoring via clinicians. “Clinician adoption is the most important thing,” said Harb. “We started with just one hospital, and now we’re in over 22 and growing every month, and have successfully expanded to the UK.”

Happitech complements the existing cardiac monitoring solutions but addresses a critical gap: an affordable, scalable, and long-term monitoring solution for better AFib detection. Happitech allows for long-term, intermittent monitoring using only a smartphone. “There’s a gap in what physicians can prescribe, limited-time Holter monitors or costly implantables,” Harb explained. “We enable clinicians to monitor patients using smartphone-based technology embedded within existing apps, offering low-cost, long-term access without the need for additional devices.”


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-happitech-turning-smartphones-into-the-first-line-of-defense-for-heart-health 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more